AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17331753
Drug: 2.5% lidocaine/2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% lidocaine/2.5% prilocaine (Oraqix) gel
Trial: 15672120
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate 1000 mg/day
Trial: 15672120
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate 2000 mg/day
Trial: 9541154
Drug: 75 mg/day
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/day venlafaxine
Trial: 9541154
Drug: 225 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg/day venlafaxine
Trial: 9541154
Drug: 375 mg/day
RxNorm normalized name: estradiol 0.0375 MG/DayTransdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg/day venlafaxine
Trial: 8014524
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate vaccine (PRP-T)
Trial: 8014524
Drug: Reconstituted lyophilized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted lyophilized PRP-T vaccine
Trial: 21204607
Drug: Cetrorelix (CTX)
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix (CTX) 3.0 mg
Trial: 18762208
Drug: NHTG2 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NHTG2 (4 mg)
Trial: 9593024
Drug: Vaccine group
RxNorm normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine group (2 doses of whole, killed promastigote vaccine cocktail plus BCG adjuvant)
Trial: 9593024
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 doses of BCG only)
Trial: 3136608
Drug: All concentrations
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All concentrations of vaccine
Trial: 31837276
Drug: Standardised home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised home exercise jaw opening and chewing programmes, and home oral hygiene measures instructed and controlled by a trained dentist.
Trial: 28604618
Drug: Trans-resveratrol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-resveratrol (2 × 75 mg/day) for 4 weeks
Trial: 27807887
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules for 4 weeks
Trial: 17439539
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) aerosols with MMAD of 1.5 microm
Trial: 17439539
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) aerosols with MMAD of 2.5 microm
Trial: 17439539
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) aerosols with MMAD of 4.5 microm
Trial: 16307696
Drug: Metopimazine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metopimazine (15 mg tid) with methylprednisolone (48 mg)
Trial: 16307696
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg bid) with methylprednisolone (48 mg)
Trial: 11950706
Drug: Fenofibrate treatment
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate treatment in 20 low-HDL subjects
Trial: 10710176
Drug: Melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin treatment (low doses in the afternoon)
Trial: 7628885
Drug: Long-term oral
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oral anticoagulant treatment after myocardial infarction
Trial: 2487802
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg a day
Trial: 2487802
Drug: Nifedipine retard
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine retard 20 mg b.i.d.
Trial: 2487802
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg and Nifedipine retard 20 mg once a day
Trial: 31629805
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream 1.5% BID
Trial: 25516316
Drug: Turmeric (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric (1 g)
Trial: 25516316
Drug: Cinnamon (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon (2 g)
Trial: 25516316
Drug: Turmeric (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric (1 g) with white bread
Trial: 12860337
Drug: Extraamniotic prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraamniotic prostaglandin E2 (PGE2) applied in serial doses of 200 mcg every 2 h up to 20 doses.
Trial: 12860337
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of oxytocin added when fetus was not expelled.
Trial: 10923280
Drug: Policosanol 5
RxNorm normalized name: policosanol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 5 mg/day for 12 weeks
Trial: 10923280
Drug: Policosanol 10
RxNorm normalized name: policosanol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 10 mg/day for 12 weeks
Trial: 8638517
Drug: 5 ppm
RxNorm normalized name: silver nitrate 55 PPM TOPICAL GEL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ppm hydrogen sulfide (H2S) inhalation
Trial: 1433583
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (reimplantation)
Trial: 31254596
Drug: Obeticholic acid
RxNorm normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Obeticholic acid (OCA) 25 mg/day for 3 weeks
Trial: 29283177
Drug: UAB criteria
RxNorm normalized name: DIMETHICONE 1 g in 100 mL TOPICAL GEL [JAFRA Fruteria So Citrico]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UAB criteria (AVF outflow vein lumen diameter ≥4 mm and blood flow ≥500 mL/min)
Trial: 29283177
Drug: NKF criteria
RxNorm normalized name: DIMETHICONE 1 g in 100 mL TOPICAL GEL [JAFRA Fruteria So Citrico]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKF criteria (AVF outflow vein lumen diameter ≥6 mm and blood flow ≥600 mL/min)
Trial: 26750378
Drug: Concentrated ambient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated ambient coarse PM (164.2 ± 80.4 μg/m(3))
Trial: 20838372
Drug: Esmolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (1 mg kg‐1)
Trial: 20838372
Drug: Landiolol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (0.2 mg kg‐1)
Trial: 20838372
Drug: Control (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.1 mL kg‐1 saline)
Trial: 12153738
Drug: Dexamethasone (DEX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (DEX), 0.1 mg twice daily for 3 days
Trial: 9035660
Drug: Nasal douche
RxNorm normalized name: Alkalol Nasal Douche Cup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal douche (saline solution)
Trial: 9035660
Drug: Hand irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand irrigation (saline solution)
Trial: 1820757
Drug: Lithium augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium augmentation for 2 weeks
Trial: 1820757
Drug: Lithium augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium augmentation for 4 weeks
Trial: 6366345
Drug: 1% Indomethacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Indomethacin solution, 1 drop 4 times daily for 3 months
Trial: 6366345
Drug: Placebo, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 drop 4 times daily for 3 months
Trial: 21388398
Drug: Hormones secreted
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormones secreted by the pituitary gland
Trial: 17009067
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (4-6 IU/hour for 3-5 days)
Trial: 17009067
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion + pioglitazone (15 mg/day)
Trial: 17009067
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion without pioglitazone
Trial: 2878025
Drug: Changing administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Changing administration sets every 24 h
Trial: 2878025
Drug: Changing administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Changing administration sets every 120 h
Trial: 27980409
Drug: Vilazodone 40
RxNorm normalized name: vilazodone 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilazodone 40 mg/d
Trial: 22842368
Drug: Combination exercise
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination exercise training (15 weeks, 2 sessions per week of walking and 2 sessions per week of resistance training)
Trial: 20566009
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate plus zoledronic acid (4 mg intravenously every 3 months)
Trial: 19368963
Drug: Visual Analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual Analog Scale (VAS) score treatment
Trial: 9466096
Drug: Metoclopramide 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.4 mg kg‐1
Trial: 3335729
Drug: Habit training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habit training and oxybutynin (2.5 mg three times daily for 1 week, then 5 mg three times daily for 1 week)
Trial: 1974399
Drug: Cetirizine 2.5
RxNorm normalized name: Levocetirizine 2.5mg/5mL Oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine 2.5 mg
Trial: 29621568
Drug: Experimental solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental solution containing NaF/TiF4 (189 ppm Ti+4, 500 ppm F‐, pH 4.4)
Trial: 29621568
Drug: Commercial solution
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial solution containing SnCl2/NaF/AmF (800 ppm Sn+2, 500 ppm F‐, pH 4.5, Elmex®/GABA, positive control)
Trial: 27697553
Drug: Methamphetamine 15
RxNorm normalized name: methamphetamine 15 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine 15 mg
Trial: 27697553
Drug: Methamphetamine 30
RxNorm normalized name: butabarbital/methamphetamine 30 mg-10 mg ORAL TABLET, EXTENDED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine 30 mg
Trial: 27697553
Drug: Buspirone 30
RxNorm normalized name: busPIRone 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 30 mg + Methamphetamine 15 mg
Trial: 27697553
Drug: Buspirone 30
RxNorm normalized name: busPIRone 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 30 mg + Methamphetamine 30 mg
Trial: 27697553
Drug: Buspirone 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 0 mg + Methamphetamine 15 mg
Trial: 27697553
Drug: Buspirone 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 0 mg + Methamphetamine 30 mg
Trial: 21298840
Drug: Centella asiatica
RxNorm normalized name: Centella asiatica
DrugBank: Centella asiatica (DB14256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centella asiatica extract capsule (50 mg of extracted asiaticoside per capsule, 2 capsules after meals, three times a day)
Trial: 17682639
Drug: 35% potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% potassium nitrate/20% benzocaine/10% tetracaine/aqueous hydroxyethyl cellulose gel
Trial: 17682639
Drug: Hydroxyethyl cellulose
RxNorm normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl cellulose without active agents
Trial: 15692981
Drug: Local steroid
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local steroid injection
Trial: 16091398
Drug: Local steroid
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local steroid injection and Physiotherapy
Trial: 12401641
Drug: Tandospirone 30
RxNorm normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandospirone 30 mg (T30 group)
Trial: 12401641
Drug: Tandospirone 10
RxNorm normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandospirone 10 mg (T10 group)
Trial: 10091630
Drug: One piribedil
RxNorm normalized name: piribedil
DrugBank: Piribedil (DB12478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One piribedil patch (1 PP)
Trial: 10091630
Drug: Two piribedil
RxNorm normalized name: piribedil
DrugBank: Piribedil (DB12478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two piribedil patches (2 PP)
Trial: 7792499
Drug: Single 400-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 400-mg dose of caffeine
Trial: 7792499
Drug: Repeated doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of caffeine (150 or 300 mg every 6 hours)
Trial: 7792499
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (no nap and placebo administered every 6 hours)
Trial: 2237331
Drug: Minnesota model
RxNorm normalized name: influenza A virus A/Minnesota/41/2019 (H3N2) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minnesota model treatment for alcohol abuse
Trial: 2407911
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment for alcohol abuse
Trial: 327652
Drug: Subcutaneous bethanechol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous bethanechol chloride 5 mg
Trial: 327652
Drug: Oral bethanechol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bethanechol chloride 100 mg
Trial: 327652
Drug: Oral bethanechol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bethanechol chloride 200 mg
Trial: 30860573
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus AKT inhibitor capivasertib
Trial: 24408035
Drug: Parenteral ω‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral ω‐3
Trial: 24320057
Drug: Broad-spectrum sunscreen
RxNorm normalized name: Titanium Dioxide 0.08 g in 1 g TOPICAL LOTION [ZO MEDICAL OCLIPSE-C Broad-Spectrum Sunscreen SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum sunscreen with anti-inflammatory agents starting on the first day after laser treatment.
Trial: 24320057
Drug: Control side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control side treated with petrolatum ointment only.
Trial: 22741251
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium Carbonate D3 tablets (600 mg, twice a day)
Trial: 15204148
Drug: New regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New regimen of fusidic acid suspension (20 mg/kg divided b.i.d.)
Trial: 15204148
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of fusidic acid suspension (50 mg/kg divided t.i.d.)
Trial: 14615175
Drug: Silicone breast
RxNorm normalized name: Tommee Tippee Silicone Breast Pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone breast implants (SBI)
Trial: 31797039
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment (2 times weekly for 5 weeks)
Trial: 31797039
Drug: Consecutive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consecutive treatment (5 times weekly for 2 weeks)
Trial: 30409184
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g of fructose (supplied in a 2‐L volume of 10% fructose in water) daily for 2 weeks
Trial: 28079600
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (4×2.5 mg/kg)
Trial: 21978382
Drug: GJS (water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GJS (water extract granules, 3 g/pack, 3 times a day) with Duolac7S (powder form, 1 capsule, 2 times a day)
Trial: 8836914
Drug: Interferon (IFN)‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN)‐alpha therapy
Trial: 28317503
Drug: Topiramate (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (maximum dosage 200 mg/day) with brief counseling
Trial: 24739538
Drug: 10-mg azilsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg azilsartan
Trial: 24739538
Drug: 8-mg candesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-mg candesartan cilexetil
Trial: 21551316
Drug: Subcutaneous albinterferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous albinterferon alfa-2b (albIFN) doses (900-1800 µg once every 2 or 4 weeks) administered for either 24 weeks (HCV genotypes 2/3) or 48 weeks (genotype 1), plus daily oral ribavirin
Trial: 21551316
Drug: Subcutaneous albinterferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous albinterferon alfa-2b (albIFN) doses (900-1800 µg once every 2 or 4 weeks)
Trial: 14694241
Drug: Non-sequential regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-sequential regimen of Budesonide 1600 microg/day for 2 weeks
Trial: 14694241
Drug: Budesonide (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (various doses)
Trial: 2245968
Drug: Recombinant‐DNA human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant‐DNA human growth hormone treatment
Trial: 6999640
Drug: Bicitropeptide (BCP-Compound)
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicitropeptide (BCP-Compound)
Trial: 11181380
Drug: SCH27899 (Ziracin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH27899 (Ziracin) 1 mg/kg
Trial: 11181380
Drug: SCH27899 (Ziracin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH27899 (Ziracin) 3 mg/kg
Trial: 11181380
Drug: SCH27899 (Ziracin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH27899 (Ziracin) 6 mg/kg
Trial: 11181380
Drug: SCH27899 (Ziracin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH27899 (Ziracin) 9 mg/kg
Trial: 11181380
Drug: Repeated doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of SCH27899
Trial: 3069879
Drug: Isocarboxazid treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocarboxazid treatment
Trial: 30657100
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate and chondroitin sulfate capsules (GS/CS)
Trial: 29656600
Drug: Sucroferric oxyhydroxide
RxNorm normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucroferric oxyhydroxide (SFOH) 1.0-3.0 g/day
Trial: 27434393
Drug: Sevelamer carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer carbonate (SEV) 2.4-14.4 g/day
Trial: 24750568
Drug: Pro-AMP cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro-AMP cream
Trial: 24750568
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (emollient cream)
Trial: 12472205
Drug: Single heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single heparin administration site
Trial: 12472205
Drug: Double site
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double site heparin administration
Trial: 8647351
Drug: Propranolol (beta-adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (beta-adrenoceptor antagonist)
Trial: 8077800
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of phosphocreatine in 200 ml of solvent for 10 days (Group 1)
Trial: 180393
Drug: Weekly 5‐fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly 5‐fluorouracil, intravenously
Trial: 180393
Drug: Daily physiologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physiologic doses of conjugated estrogens by mouth